Prostamax
Also called KEDP; Lys-Glu-Asp-Pro
A four-amino-acid bioregulator peptide studied in prostate tissue and cellular-aging experiments. It is not an established treatment for prostatitis or an enlarged prostate.
Overview
What it is
A synthetic tetrapeptide of lysine, glutamic acid, aspartic acid and proline.
How it works
In cells from donors aged 75 to 86, it loosened DNA packaging (chromatin). That is not DNA repair or reversed aging.
What the research shows
In 60 rats with induced non-bacterial prostate inflammation, it reduced swelling and inflammatory cells, but prostate size did not change significantly. A Russian patent describes improvements in 35 prostatitis and 19 prostate adenoma patients, without randomization or blinding.
Studied for
- Prostate inflammationrats
- Chromatin in older donors' cellslab
- Prostatitis and BPHpatent reports
Safety and regulatory status
Safety and side effects
No reliable human side-effect, interaction or long-term data. Do not stop prescribed prostate treatment. Seek prompt care for inability to urinate, blood in urine, severe lower abdominal pain, or painful urination with fever.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
Prostamax (20 mg Vial) Dosage Protocol
- Vial
- 20 mg Prostamax
- Add diluent
- 2 mL
- Concentration
- 10 mg/mL
- 1 unit (U-100)
- 100 mcg in 0.01 mL
- Route
- Intramuscular
- How often
- Once per day (intramuscular).
- Typical range
- 500 mcg–1 mg once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Phase / Week | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
How to mix
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; follow product-specific use-by instructions.
Dosing details
- Start: 500 mcg (0.5 mg) daily; increase by ~250 mcg every 2 weeks as tolerated.
- Target: 1 mg daily by Weeks 5–8.
- Frequency: Once per day (intramuscular).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites among large muscle groups.
Storage
- Lyophilized: Follow the exact product’s labeled storage temperature and expiration instructions; keep the vial dry and protected from light.
- Temperature changes: Do not assume refrigeration or freezing extends a product’s expiration date without validated evidence.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions and avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Intramuscular administration guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- For IM injection, use a 22–25 gauge, 1–1.5 inch needle inserted at 90° into a large muscle (deltoid, vastus lateralis, or gluteus).
- Aspiration before IM injection is no longer routinely recommended for most sites.
- Inject slowly and steadily; wait briefly before withdrawing.
- Rotate sites systematically to avoid muscle irritation or fibrosis.
- Alternative (SC): If subcutaneous route is preferred, use a 23–25 gauge, 5/8 inch needle at 45° into fatty tissue.
Important notes
- Use new sterile insulin syringes or appropriate IM syringes; dispose in a sharps container.
- Rotate injection sites among large muscle groups (deltoid, vastus lateralis, gluteus) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- For volumes ≤10 units, use 30‑ or 50‑unit syringes for better precision.
- Document daily dose and site rotation to maintain consistency.
Protocol source: PeptideDosages.com
Common questions
Does Prostamax shrink the prostate?
Not shown; prostate size did not change significantly in the rat study.
Do human-cell studies mean it works in people?
No. They show biological activity, not patient benefit.
Is prostatitis the same as BPH?
No. One is inflammation, the other is non-cancerous enlargement.
Related in Hormones and Reproductive Health
Sources and further reading (4)
- Dzhokhadze TA, et al. KEDP and chromatin in older-donor cells. Georgian Med News, 2012.
- Borovskaya TG, et al. Prostamax in experimental chronic aseptic prostatitis. Mod Res Inflamm, 2013.
- NIDDK. Prostatitis; Enlarged prostate (BPH).
- Source summary: PeptideDosages.com research overview (rewritten for NVO).